Cormorant Asset Management, LP Astria Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.99 - $16.69 $9.09 Million - $21.7 Million	1,300,000 New	1,300,000 $18.3 Million
Q1 2023 May 15, 2023	SELL	$11.2 - $15.79 $7.28 Million - $10.3 Million	-650,000 Reduced 39.39%	1,000,000 $13.3 Million
Q4 2022 Feb 14, 2023	BUY	$7.44 - $14.89 $3.35 Million - $6.7 Million	450,000 Added 37.5%	1,650,000 $24.6 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $10.34 $2.67 Million - $9.31 Million	900,000 Added 300.0%	1,200,000 $10.8 Million
Q1 2022 May 16, 2022	SELL	$3.92 - $7.1 $991,379 - $1.8 Million	-252,903 Reduced 45.74%	300,000 $2.01 Million
Q3 2021 Nov 15, 2021	BUY	$7.32 - $12.9 $4.05 Million - $7.13 Million	552,903 New	552,903 $4.89 Million

107

48.6M

48K

9.3K

Ticker ATXS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,178,000
Market Cap $150M
Description
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.